021-51111890
购物车（）
sales@molnova.cn
Encorafenib
CAS No. 1269440-17-6
Encorafenib ( LGX818; LGX-818; LGX 818; Encorafenib )
产品货号. M17919 CAS No. 1269440-17-6
LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
纯度: 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥697 | 有现货 |
|
| 10MG | ￥1004 | 有现货 |
|
| 25MG | ￥1596 | 有现货 |
|
| 50MG | ￥3029 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Encorafenib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
-
产品描述Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
-
同义词LGX818; LGX-818; LGX 818; Encorafenib
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体B-Raf (V600E)
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1269440-17-6
-
分子量540.01
-
分子式C22H27ClFN7O4S
-
纯度98%
-
溶解度DMSO : 50 mg/mL 92.59 mM;
-
SMILESC[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=CC(=CC(=C3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
-
化学全称(S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate.
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Darrin D Stuart, et al. Cancer Res, 2012, 72(8 Supplement): 3790.
